31 December 2015 - The first issue of the New Zealand Pharmaceutical Schedule for 2016 sees the listing of a new medicine: icatibant acetate (Firazyr) for the emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema for patients with confirmed diagnosis of C1-esterase inhibitor deficiency.

For more details, go to: http://www.pharmac.govt.nz/2015/12/16/SU.pdf